Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sawai Snaps Up Rights for ALS Drug Candidate from Tokai Univ. Spin-Off, Its 1st Orphan Development
Japanese generic major Sawai Pharmaceutical said on June 22 that it has entered into a codevelopment and exclusive license agreement with Neugen Pharma for the rights to manufacture and market the Tokai University spin-off's amyotrophic lateral sclerosis (ALS) drug candidate…
To read the full story
Related Article
BUSINESS
- Canada Backs Public Reimbursement of Leqembi
September 2, 2026
- Marubeni Pharma Sets Up Hong Kong Subsidiary
September 2, 2026
- Enhertu Combo Snags EU Nod in 1st-Line HER2 Breast Cancer
September 2, 2026
- Shionogi Pivoting to Function-Based Model in Global HR Revamp
September 1, 2026
- SanBio to Move All Akuugo Manufacturing to Minaris’ Yokohama Site
September 1, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…